@article{072a6700538f4f4b8146cfc108b77dd7,
title = "Doubling the blockade for melanoma immunotherapy",
keywords = "CTLA4, PD-1, ipilimumab, metastatic melanoma, nivolumab, pembrolizumab",
author = "Lorenzo Galluzzi and Alexander Eggermont and Guido Kroemer",
note = "Funding Information: Authors are supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche M{\'e}dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).",
year = "2016",
doi = "10.1080/2162402X.2015.1106127",
language = "English",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Ltd.",
number = "1",
}